Xenon制药宣布,其针对局灶性癫痫发作(FOS)的研究药物Azetukalner,在关键3期临床试验X-Tole2中获得了积极的顶线结果。该数据标志着公司在癫痫治疗领域研发的重要进展。
Xenon制药宣布,其针对局灶性癫痫发作(FOS)的研究药物Azetukalner,在关键3期临床试验X-Tole2中获得了积极的顶线结果。该数据标志着公司在癫痫治疗领域研发的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.